Fermenta Biotech Limited (BOM:506414)
India · Delayed Price · Currency is INR 458.25
+8.85 (1.97%)
At close: Aug 17, 2026
Fermenta Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 5,110 | 5,254 | 4,695 | 3,357 | 3,499 | 3,985 | |
Revenue Growth | -3.15% | 11.92% | 39.87% | -4.08% | -12.19% | 5.63% |
Cost of Revenue | 2,043 | 2,142 | 1,844 | 1,534 | 1,698 | 1,670 |
Gross Profit | 3,067 | 3,112 | 2,851 | 1,822 | 1,801 | 2,315 |
Selling, General & Admin | 937.46 | 910.9 | 704.4 | 620.8 | 618.6 | 660.6 |
Other Operating Expenses | 1,233 | 1,203 | 998.79 | 923 | 1,003 | 1,039 |
Operating Expenses | 2,381 | 2,331 | 1,945 | 1,791 | 1,904 | 1,955 |
Operating Income | 685.73 | 781.37 | 905.42 | 31.17 | -103.27 | 359.77 |
Interest Expense | -109.72 | -115.38 | -141.92 | -170.46 | -207.82 | -162.69 |
Interest & Investment Income | 56.17 | 56.17 | 36.63 | 44.77 | 29.42 | 13.16 |
Currency Exchange Gain (Loss) | 104.62 | 104.62 | 46.19 | 12.57 | 21.08 | 29.99 |
Other Non Operating Income (Expenses) | -40.92 | 3.06 | 2.72 | 6.12 | 2.17 | 9.78 |
EBT Excluding Unusual Items | 695.88 | 829.84 | 849.04 | -75.84 | -258.43 | 250.02 |
Impairment of Goodwill | - | - | - | -74.26 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.59 |
Gain (Loss) on Sale of Assets | 1.05 | 1.05 | -49.6 | -3.26 | -3.15 | -0.27 |
Other Unusual Items | 100.21 | 100.21 | 14.79 | 54.09 | -251.6 | 12.81 |
Pretax Income | 824.65 | 958.61 | 832.08 | -98.73 | -513.05 | 269.43 |
Income Tax Expense | 242.81 | 256.06 | 68.05 | 141.36 | 18.27 | 118.83 |
Earnings From Continuing Operations | 581.84 | 702.54 | 764.03 | -240.09 | -531.32 | 150.61 |
Minority Interest in Earnings | 14.84 | 15.11 | 4.59 | 9.49 | 20.57 | 3.87 |
Net Income | 596.69 | 717.65 | 768.62 | -230.6 | -510.75 | 154.47 |
Net Income to Common | 596.69 | 717.65 | 768.62 | -230.6 | -510.75 | 154.47 |
Net Income Growth | -42.91% | -6.63% | - | - | - | -66.05% |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Change | 0.05% | 0.35% | 1.04% | 0.06% | -0.50% | -0.01% |
EPS (Basic) | 20.63 | 24.70 | 26.35 | -7.99 | -17.70 | 5.35 |
EPS (Diluted) | 20.39 | 24.51 | 26.35 | -7.99 | -17.70 | 5.33 |
EPS Growth | -42.95% | -6.98% | - | - | - | -66.03% |
Free Cash Flow | - | 624.99 | 187.69 | 861.39 | 756.19 | 63.13 |
Free Cash Flow Per Share | - | 21.35 | 6.43 | 29.83 | 26.20 | 2.18 |
Dividend Per Share | - | 3.750 | 2.500 | 1.250 | 1.250 | 1.250 |
Dividend Growth | - | 50.00% | 100.00% | 0% | 0% | -50.00% |
Gross Margin | 60.02% | 59.23% | 60.72% | 54.29% | 51.47% | 58.09% |
Operating Margin | 13.42% | 14.87% | 19.29% | 0.93% | -2.95% | 9.03% |
Profit Margin | 11.68% | 13.66% | 16.37% | -6.87% | -14.59% | 3.88% |
Free Cash Flow Margin | - | 11.89% | 4.00% | 25.66% | 21.61% | 1.58% |
EBITDA | 883.16 | 984.82 | 1,133 | 262.68 | 161.4 | 591.74 |
EBITDA Margin | 17.28% | 18.74% | 24.13% | 7.83% | 4.61% | 14.85% |
D&A For EBITDA | 197.43 | 203.45 | 227.5 | 231.52 | 264.67 | 231.96 |
EBIT | 685.73 | 781.37 | 905.42 | 31.17 | -103.27 | 359.77 |
EBIT Margin | 13.42% | 14.87% | 19.29% | 0.93% | -2.95% | 9.03% |
Effective Tax Rate | 29.44% | 26.71% | 8.18% | - | - | 44.10% |
Revenue as Reported | 5,290 | 5,478 | 4,813 | 3,475 | 3,585 | 4,067 |
Advertising Expenses | - | 66.87 | 43.35 | 26.45 | 29.16 | 24.96 |